This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Fusion Antibodies Limited. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Darragh McMeel: Innovator in Cancer Therapy
Introduction
Darragh McMeel is a notable inventor based in Belfast, GB. He has made significant contributions to the field of cancer therapy, particularly through his innovative approaches to targeting specific proteins involved in tumor growth.
Latest Patents
Darragh McMeel holds a patent for a method of inhibiting chemotherapy-induced upregulation of Cathepsin S on the surface of tumor cells. This invention involves the administration of a Cathepsin S inhibitor to these cells. Additionally, his patent includes a therapy comprising an anti-Cathepsin S antibody, which does not inhibit the proteolytic effect of Cathepsin S but effectively inhibits angiogenesis. Furthermore, he has developed a combination treatment that includes a Cathepsin S inhibitor and a therapeutic agent.
Career Highlights
Darragh McMeel is associated with Fusion Antibodies Limited, where he applies his expertise in developing innovative cancer therapies. His work focuses on enhancing the effectiveness of chemotherapy treatments and improving patient outcomes.
Collaborations
Darragh collaborates with talented professionals in his field, including Roberta Burden and James Johnston. Their combined efforts contribute to advancing research and development in cancer therapies.
Conclusion
Darragh McMeel's innovative work in cancer therapy, particularly through his patent targeting Cathepsin S, showcases his commitment to improving treatment options for patients. His contributions are vital in the ongoing fight against cancer.